Equity
€71,137 from €162,433 in 2020
Equity fell by 56% in 5 years.
Pharma More Management
Lifetime
15 annual accounts with figures on one time axispeak €490,646 (2019)
€54,742▲ 41.4%
lowest -€34,960 (2011)
€15,478▲ 14×
peak €162,433 (2020)
€71,137▲ 27.8%
€259,778▲ 4.9%
peak 7.2 FTE (2020)
-not published
Board2 names since 2020
1 directorVAN DE WALLE Dries
Documentsfilings and deeds
29-07-20262 days before the deadline
2025micro format
Gross margin from €38,717 to €54,742Result from €1,104 to €15,478Equity from €55,659 to €71,137
Key points
from the 2025 annual accountsDebts
€259,778 79% of the balance sheet
Financial debts 80%Suppliers 6%Taxes and wages 6%Other 9%
Of this, €67,704 falls due within a year.
Liquidity
1.19 was 0.67 in 2024
Short-term debts rose from €34,846 to €67,704.
Financial institution: outside the model
Bankruptcy probability
Outside the general model
Model not applicable to financial institutions
The Checked score measures liquidity, leverage and margins against the norms for trading and manufacturing companies. A bank, insurer or financial holding has a very different balance sheet. Those ratios and the score mean nothing here. So there is no financial strength either.
Bankruptcy probability within 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.4% across 26,888 companies (NACE 46, micro).
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 1.5%
01-2025: 1.5%● unchanged vs 12-2024
02-2025: 1.5%● unchanged vs 01-2025
03-2025: 1.5%● unchanged vs 02-2025
04-2025: 1.5%● unchanged vs 03-2025
05-2025: 1.4%▼ -0.1 percentage points vs 04-2025
06-2025: 1.4%● unchanged vs 05-2025
07-2025: 1.5%▲ +0.1 percentage points vs 06-2025
08-2025: 2.0%▲ +0.5 percentage points vs 07-2025
09-2025: 2.2%▲ +0.2 percentage points vs 08-2025highest value
10-2025: 0.5%▼ -1.7 percentage points vs 09-2025
11-2025: 0.5%● unchanged vs 10-2025
12-2025: 0.5%● unchanged vs 11-2025
01-2026: 0.5%● unchanged vs 12-2025
02-2026: 0.5%● unchanged vs 01-2026
03-2026: 0.5%● unchanged vs 02-2026
04-2026: 0.4%▼ -0.1 percentage points vs 03-2026
05-2026: 0.4%● unchanged vs 04-2026
06-2026: 0.4%● unchanged vs 05-2026
07-2026: 0.4%● unchanged vs 06-2026
08-2026: 0.2%▼ -0.2 percentage points vs 07-2026lowest value
09-2026: 0.2%● unchanged vs 08-2026lowest value
10-2026: 0.2%● unchanged vs 09-2026lowest value
11-2026: 0.2%● unchanged vs 10-2026lowest value
Comparable companies, two years later
In July 2024, 4,508 companies had the same profile as Pharma More Management has now. Each dot stands for 12 companies, two years later.
96.9%
were still trading
1.6%
stopped another way
1.4%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of Pharma More Management itself: 0.2% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 4,508 companies, not a prediction for Pharma More Management. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
2 days early
2024
30 days late
2023
30 days late
2022
32 days late
2021
31 days late
2020
31 days late
2019
39 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 27 days after the deadline. In the sector (NACE 64), the median for financial year 2024 was 14 days before the deadline, and 28% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 31 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0831762330
Demerger: Pharma & More splits off to Pharma & More
Company renamed to Pharma More Management · New name: Pharma More Management · Issue of 1,500 shares · General meeting of 17-09-2021 · Gazette deed
Demerger proposal: Pharma & More splits off to Pharma & More
Appointment: J.VANDE MOORTEL & C° BEDRIJFSREVISOREN (statutory auditor) · Dries Van De Walle holds 186 shares (100%) · Gazette deed
Capital increase of €100,000
1,000 new shares · Capital contribution: Tweede beslissing · Change of role: VAN DE WALLE Dries, from statutory director to director · General meeting of 14-10-2020 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Pharma More Management Destelbergen | €330,915 | €54,742 | 21.5% | - |
| VP SERVICE Brakel | €321,323 | €60,899 | 14.0% | - |
| 10be Kruisem | €318,733 | €61,956 | 86.3% | - |
| TC BUILDING Maldegem | €264,344 | €55,951 | 67.0% | - |
| NICSAN Lokeren | €359,825 | €61,557 | -13.2% | - |
| MARPINIC Brasschaat | €348,824 | €51,778 | 86.4% | - |
| COWECO Antwerp | €322,617 | €55,030 | 92.9% | - |
These companies have the same main activity as Pharma More Management: activities of holding companies (NACE 64210). They are comparable in size and age: total assets between €264,000 and €360,000, founded between 2009 and 2011.
Official details
Source: KBO- Status
- Active since 09-12-2010Normal situation
- Activity
- Activities of holding companiesNACE 64210and 1 other
- Establishment unit
- 2.195.442.5709070 Destelbergen, since 09-12-2010
- Financial year end
- 31 December
- Peppol
- Reachable since 15-01-2026
Annual accounts 2025
- €330,915▲ 9.1%
- Filing
- Filed on 29-07-2026, 2 days before the end of the filing period
Insights on Pharma More Management
Pharma More Management files the micro format. That format states no turnover. The gross margin rose from -€28,561 in 2011 to €54,742 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Pharma More Management
- What is the company number of Pharma More Management?
- The company number of Pharma More Management is 0831.762.330. The VAT number is the same number with BE in front: BE 0831.762.330.
- Where is Pharma More Management based?
- The registered office is at Bommelsrede 45, 9070 Destelbergen.Company details
- What does Pharma More Management do?
- According to the KBO register, the main activity is activities of holding companies (NACE 64210).
- What is the legal form of Pharma More Management?
- Pharma More Management is a private limited company (BV).
- When was Pharma More Management founded?
- Pharma More Management was founded on 09-12-2010.
- Is Pharma More Management still active?
- Yes, Pharma More Management is an active enterprise in the KBO register.
- How many employees does Pharma More Management have?
- Pharma More Management had an average of 7.2 full-time equivalents in financial year 2020, according to the filed annual accounts.Financials
- What is the turnover of Pharma More Management?
- The turnover in financial year 2025 is ≈ €130,000. This figure is estimated from the gross margin of €54,742 and 40 comparable companies (NACE 64210). It probably lies between €82,000 and €160,000.
- Is Pharma More Management profitable?
- In financial year 2025, Pharma More Management made a profit of €15,478.
- Where can I find the annual accounts of Pharma More Management?
- Pharma More Management filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Pharma More Management due?
- Pharma More Management must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See what changed in the latest annual accounts.What changed See this company's board, registered office and name on a given date.Company as of a date
See how customers, suppliers and banks see your own company and what to improve first.